A multi-omics study reveals that impaired branched-chain amino acid (BCAA) catabolism is a key driver of sarcopenia, suggesting it as a potential therapeutic target.
Cases of severe RSV in two Moderna vaccine candidates’ trials raise questions about future
Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS